On July 1, 2025, ATAI Life Sciences N.V. entered into agreements for a private investment in public equity (PIPE Financing), raising approximately $50 million by selling around 18.3 million shares at $2.19 each, and involving pre-funded warrants. The financing supports working capital and clinical development, and follows an earlier acquisition of Beckley Psytech shares.